EN | RU
EN | RU

Help Support

Back

GMA use boosts survival rates in patients with severe alcohol-associated hepatitis

Severe alcohol-associated hepatitis Severe alcohol-associated hepatitis
Severe alcohol-associated hepatitis Severe alcohol-associated hepatitis

What's new?

People with severe alcohol-associated hepatitis who are not responsive to or intolerant of conventional treatments may experience improved survival benefits at 90 and 180 days with the use of granulocyte-monocyte/macrophage apheresis.

In a prospective, open-label, nonrandomized study, granulocyte-monocyte/macrophage apheresis (GMA) demonstrated a lower-than-expected 90- and 180-day mortality compared to published studies in patients suffering from steroid-nonresponsive or steroid-intolerant severe alcohol-associated hepatitis. Researchers sought to examine whether GMA use improves survival rates in severe alcohol-associated hepatitis.

Hepatitis-affected individuals, identified as nonresponsive or intolerant to corticosteroids based on the Lille model and Model for End-stage Liver Disease (MELD) score criteria, and fulfilling specific inclusion criteria (such as leukocytosis over 10,000/μL), were contemplated for recruitment. Following the standard of care, subjects were included with a median duration of 23 days (interquartile range [IQR], 14-31 days) from admission. The efficiency of GMA using Adacolumn, conducted twice per week for up to ten sessions per treatment course, was examined.

A total of 13 GMA treatments were executed in this pilot study. At the time of admission, the Maddrey Discriminant Function was 53.2 ± 17.7. As found, the overall survival rate at 90 and 180 days was 90.9%. Following GMA, there was a remarkable betterment in MELD scores, decreasing from a median (IQRs) of 23 (20-25) to 15 (13-21) (p<0.0001). The anticipated mortality risks, examined utilizing the Lille model and MELD scores, also considerably improved from 20.9%±16.5% to 7.4%±7.3% at two months and from 30.4%±21.3% to 11.6%±10.8% at six months, respectively (both p<0.01), with internal validation.

The alcohol relapse cumulative rate was 35.9% per year. There were no severe noxious events documented. In the exploratory assessment, granulocyte colony-stimulating factor levels exhibited a pivotal correlation with prognostic systems like MELD-Sodium scores following GMA (correlation coefficient= -0.9943, p<0.0001) but not before GMA (p=0.62). Hence, GMA could serve as a potentially beneficial salvage anti-inflammatory therapy for severe alcohol-associated hepatitis patients who do not respond well to conventional treatments.

Source:

Hepatology Communications

Article:

Granulocyte-monocyte/macrophage apheresis for steroid-nonresponsive or steroid-intolerant severe alcohol-associated hepatitis: A pilot study

Authors:

Ryosuke Kasuga et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: